Clinical Trials Browser

Enrolling by invitation × INDUSTRY × Irinotecan × Clear all

NCT05865925 2024-04-25

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Phase 1/2 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumors